Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes
- PMID: 498415
- DOI: 10.1007/BF00253101
Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes
Abstract
We have compared the toxicologic, pharmacologic, and therapeutic properties of the DNA complexes of daunorubicin and doxorubicin, after intravenous (IV) administration into mice. The overall toxicity of doxorubicin is significantly reduced after IV injection as a DNA complex while daunorubicin-DNA is as toxic as free daunorubicin. On hemopoietic stem cells, daunorubicin-DNA was found to be more cytotoxic than daunorubicin, while the opposite was observed with doxorubicin and doxorubicin-DNA. Both complexes are more effective than the corresponding free drugs on the L1210 murine leukemia, when given IV at equitoxic doses. The tissue uptake in mice, after IV administration, is generally lower when the drugs are given bound to DNA. The stability of the two DNA complexes is very different in the bloodstream: daunorubicin-DNA behaves more like a prodrug of daunorubicin, while doxorubicin-DNA, remaining stable in the bloodstream, meets much more the requirements of an ideal drug-macromoleculare carrier entity.
Similar articles
-
Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.Cancer Treat Rep. 1979 May;63(5):861-7. Cancer Treat Rep. 1979. PMID: 455327
-
DNA--anthracycline complexes. I. Toxicity in mice and chemotherapeutic activity against L1210 leukemia of daunorubicin--DNA and adriamycin--DNA.Eur J Cancer (1965). 1980 Aug;16(8):981-6. doi: 10.1016/0014-2964(80)90243-1. Eur J Cancer (1965). 1980. PMID: 7439227 No abstract available.
-
Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.Eur J Cancer (1965). 1979 Mar;15(3):363-71. doi: 10.1016/0014-2964(79)90048-3. Eur J Cancer (1965). 1979. PMID: 446517 No abstract available.
-
Daunomycin- and adriamycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugates; toxicity reduction by improved drug-delivery.Cancer Treat Rev. 1987 Dec;14(3-4):319-27. doi: 10.1016/0305-7372(87)90024-7. Cancer Treat Rev. 1987. PMID: 3326668 Review. No abstract available.
-
Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review.Biochimie. 1984 May;66(5):333-52. doi: 10.1016/0300-9084(84)90018-x. Biochimie. 1984. PMID: 6380596 Review.
Cited by
-
The immunoinhibitory and immunostimulatory effects of hydroxyanthra- and hydroxynaphthoquinone derivatives.Folia Microbiol (Praha). 1981;26(3):171-5. doi: 10.1007/BF02927418. Folia Microbiol (Praha). 1981. PMID: 7196864
-
Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.Cancer Chemother Pharmacol. 1981;6(1):65-73. doi: 10.1007/BF00253012. Cancer Chemother Pharmacol. 1981. PMID: 7023715 Clinical Trial.
-
Isolated cell-bound membrane vesicles (CBMVs) as a novel class of drug nanocarriers.J Nanobiotechnology. 2020 May 6;18(1):69. doi: 10.1186/s12951-020-00625-2. J Nanobiotechnology. 2020. PMID: 32375799 Free PMC article.
-
Plasma levels of doxorubicin after IV bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Comparison with free doxorubicin.Cancer Chemother Pharmacol. 1982;9(2):93-6. doi: 10.1007/BF00265386. Cancer Chemother Pharmacol. 1982. PMID: 7172411
-
DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.Cancer Chemother Pharmacol. 1979;2(1):7-10. doi: 10.1007/BF00253097. Cancer Chemother Pharmacol. 1979. PMID: 498422
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources